EHC Stock Recent News

Encompass Health's (EHC) Q3 results are likely to reflect improved inpatient volumes and bed additions, offset by higher operating expenses.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Encompass Health (EHC) is well-poised for growth on the back of growing revenues, an aging U.S. population, joint ventures and solid cash reserves.

Here is how Encompass Health (EHC) and Eton Pharmaceuticals, Inc. (ETON) have performed compared to their sector so far this year.

The Rehabilitation Hospital of Columbus is Encompass Health's (EHC) sixth location in the state of Georgia.

Here are the five stocks that meet our screening criteria - PRDO, EHC, OSK, HSBC and PHM.

HURN, EHC, RDY, BOOM and HWKN are five stocks with explosive relative price strength.

Encompass Health Corporation has revised its growth outlook and capital investment spends for FY'23. EHC's growth strategy relies on building same-store revenues and adding new facilities to its portfolio. The company's de novo model and capital deployment trends add tremendous torque to its economic flywheel.

Encompass Health's (EHC) Q2 results reflect a growing patient base and improved net patient revenue per discharge. Management anticipates 2023 adjusted EPS within $3.31-$3.53, up from the earlier view of $2.94-$3.23.

While the top- and bottom-line numbers for Encompass Health (EHC) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.